Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 9, 2015, Pages

  Mccloud, Tayla L ^a   Caddy, Caroline ^a   Jochim, Janina ^a   Rendell, Jennifer M ^a   Diamond, Peter R ^b   Shuttleworth, Claire ^a   Brett, Daniel ^a   Amit, Ben H ^c,d   Mcshane, Rupert ^e   Hamadi, Layla ^a   Hawton, Keith ^e   Cipriani, Andrea ^a,f  

^a WARNEFORD HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c TEL AVIV UNIVERSITY   (Israel)

^d GEHA MENTAL HEALTH CENTER   (Israel)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTIDINE; KETAMINE; MEMANTINE; PLACEBO; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT;

ABDOMINAL DISCOMFORT; ABNORMAL FECES; ADULT; AGITATION; ANXIETY; ARTHRALGIA; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BODY TEMPERATURE DISORDER; BODY WEIGHT LOSS; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE SEVERITY; DISSOCIATIVE DISORDER; DIZZINESS; DROWSINESS; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; ENDOCRINE DISEASE; FEAR; FLATULENCE; GASTROINTESTINAL DISEASE; HAIR LOSS; HEADACHE; HUMAN; HYPOMANIA; INSOMNIA; LEG CRAMP; LIBIDO DISORDER; MANIA; MASTALGIA; MENSTRUAL IRREGULARITY; MICTURITION DISORDER; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SKIN IRRITATION; SOMNOLENCE; SPEECH DISORDER; SUICIDE ATTEMPT; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT DURATION; TREMOR; VIVID DREAM; XEROSTOMIA; YOUNG MANIA RATING SCALE; DEPRESSION; META ANALYSIS; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CYTIDINE; DEPRESSION; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE; MEMANTINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84949860986     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011611.pub2     Document Type: Review

References (113)

1. Anand A, Gunn AD, Barkay G, Karne HS, Nurnberger JI, Mathew SJ, et al. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: A double-blind, randomized, placebo-controlled trial. Bipolar Disorders 2012;14:64-70.
2. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry 2010;67:793-802.
3. Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Roiser JP, Zarate CA. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Translational Psychiatry 2014;4:e469.
4. Lee SY, Chen SL, Chang YH, Chen PS, Huang SY, Tzeng NS, et al. The effects of add-on low-dose memantine on cytokine levels in bipolar II. depression: A 12-week double-blind, randomized controlled trial. Journal of Clinical Psychopharmacology 2014;34:337-43.
5. Yoon SJ, Lyoo IK, Haws C, Kim TS, Cohen BM, Renshaw PF. Decreased glutamate/glutamine levels may mediate cytidine's efficacy in treating bipolar depression: a longitudinal proton magnetic resonance spectroscopy study. Neuropsychopharmacology 2009;34(7):1810-8.
6. Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Roiser JP, Zarate CA. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Translational Psychiatry 2014;4:e469.
7. Zarate CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biological Psychiatry 2012;71:939-46.
8. Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biological Psychiatry 2008;64(6):468-75.
9. Chen SL, Lee SY, Chang YH, Chen PS, Wang TY, Lu RB. Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder. European Neuropsychopharmacology 2014;24(11):1753-9.
10. Cocchi R, Fusari A, Lorini G, Roccia L. Acupunctura, "vital" drugs and psychopharmacological agents in the treatment of psychiatric patients with deep depressive disorders, with considerations on the probable neurophysiological mechanisms of the synergism of action [article in Italian]. Minerva Medica 1977;68(33):2309-14.
11. Crane GE. The psychotropic effects of cycloserine: A new use for an antibiotic. Comprehensive Psychiatry 1961;2:51-9.
12. Dean O, Berk M, Cotton SM, Bush AI, Gama CS, Kapczinski F, et al. N-acetyl cysteine (NAC) as an adjunctive therapy for bipolar depression conference poster P35. Bipolar disorders. Abstracts of the 9th International Conference on Bipolar Disorder; 2011 June 9-11; Pittsburgh [PA]. 2011; Vol. 13:38.
13. Ehrensing RH, Kastin AJ. Dose-related biphasic effect of prolyl-leucyl-glycinamide (MIF-I) in depression. American Journal of Psychiatry 1978;135(5):562-6.
14. Ellis JS, Luckenbaugh DA, Zarate CA, Furey ML. Effects of ketamine versus scopolamine on individual depression and anxiety symptoms (abstract). Biological Psychiatry 2014;75:127S.
15. Lee SY, Chen SL, Chang YH, Chen SH, Chu CH, Huang SY, et al. The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder. Journal of Affective Disorders 2012;138:295-300.
16. Luckenbaugh DA, Niciu MJ, Ionescu DF, Nolan NM, Richards EM, Brutsche NE, et al. Do the dissociative side effects of ketamine mediate its antidepressant effects?. Journal of Affective Disorders 2014;159:56-61.
17. Magalhães PV, Dean OM, Bush AI, Copolov DL, Weisinger D, Malhi GS, et al. Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder. Progress in Neuropsychopharmacology and Biological Psychiatry 2012;37(1):132-5.
18. NCT01684163. Phase 2, double-blind, placebo controlled, randomized withdrawal, parallel efficacy and safety study of GLYX-13 in subjects with inadequate/partial response to antidepressants during the current episode of major depressive disorder. www.clinicaltrials.gov/show/NCT01684163.
19. NCT01306760. The use of ketamine as an anaesthetic during electroconvulsive therapy (ECT) for depression: does it improve treatment outcome?. www.clinicaltrials.gov/show/NCT01306760.
20. Rasmussen KG, Kung S, Lapid MI, Oesterle TS, Geske JR, Nuttall GA, et al. A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy. Psychiatry Research 2014;215:362-5.
21. ACTRN12612000830897. A double blind, placebo controlled, randomised trial to evaluate the effect of mitochondrial agents, N-acetyl cysteine or placebo on the depressive phase of bipolar disorder. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12612000830897.
22. ISRCTN14689382. Ketamine augmentation of ECT to improve outcomes in depression. www.isrctn.org/ISRCTN14689382.
23. NCT01881763. Comparing therapeutic efficacy and cognitive side effects of electroconvulsive therapy (ECT) using ketamine versus methohexital anesthesia. www.clinicaltrials.gov/show/NCT01881763.
24. Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here?. Biological Psychiatry 2012;72(7):537-47.
25. Abel KM, Allin MP, Kucharska-Pietura K, David A, Andrew C, Williams S, et al. Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study. Neuroreport 2003;14(3):387-91.
26. Abrams R, Morrison JE, Villasenor A, Hencmann D, Da Fonseca M, Mueller W. Safety and effectiveness of intranasal administration of sedative medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures. Anesthesia Progress 1993;40(3):63-6.
27. Akinfiresoye L, Tizabi Y. Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR. Psychopharmacology 2013;230(2):291-8.
28. Altamura C, Maes M, Dai J, Meltzer HY. Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Europen Neuropsychopharmacology 1995;5 Suppl:71-5.
29. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
30. Amit B, Caddy C, McCloud T, Rendell J, Hawton K, McShane R, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database of Systematic Reviews 2015, Issue 4. [DOI:]
31. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington D.C.: American Psychiatric Association, 1980.
32. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington D.C.: American Psychiatric Association, 1987.
33. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, D.C.: American Psychiatric Association, 1994.
34. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders - Text Revision (DSM-IV-TR). 4th Edition. Washington, D.C.: American Psychiatric Association, 2000.
35. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Arlington (VA): American Psychiatric Association, 2013.
36. Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, et al. Antidepressants versus placebo for depression in primary care. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI:]
37. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490.
38. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011;475(7354):91-5.
39. Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?. Journal of Clinical Psychiatry 2006;67(9):1428-34.
40. Bauer IE, Pascoe MC, Wollenhaupt-Aguiar B, Kapczinski F, Soares JC. Inflammatory mediators of cognitive impairment in bipolar disorder. Journal of Psychiatric Research 2014;56:18-27.
41. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nature Reviews. Neuroscience 2006;7(2):137-151.
42. Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Subgroup analyses in randomized controlled trials: quantifying the risks of false-positives and false-negatives. Health Technology Assessment 2001;5(33):1-56.
43. Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. Journal of Clinical Epidemiology 2004;57(3):229-36.
44. Browne CA, Lucki I. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Frontiers in Pharmacology 2013;4:161.
45. Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Therapeutic Advances in Psychopharmacology 2014;4(2):75-99.
46. Caddy C, Amit B, McCloud T, Rendell J, Furukawa TA, Hawton K, et al. Ketamine and other glutamate receptor modulators for depression in adults. Cochrane Database of Systematic Reviews in press.
47. Canadian Agency for Drugs and Technologies in Health. Intravenous ketamine for the treatment of mental health disorders: a review of clinical effectiveness and guidelines. http://www.cadth.ca/en/products/rapid-response/publication/4759 (accessed Aug 2014).
48. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373(9665):746-58.
49. Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, et al. Sertraline versus other antidepressive agents for depression. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI:]
50. Cipriani A, Purgato M, Furukawa TA, Trespidi C, Imperadore G, Signoretti A, et al. Citalopram versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI:]
51. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013;346:f3646.
52. Cipriani A, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, et al. Duloxetine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2012, Issue 10. [DOI:]
53. Coyle CM, Laws KR. The use of ketamine as an antidepressant: a systematic review and meta-analysis. Human Psychopharmacology: Clinical and Experimental 2015;30(3):152-63.
54. Dozois D J A, Dobson K S. Depression. In: Antony M M, Barlow D H editor(s). Handbook of Assessment and Treatment Planning for Psychological Disorders. New York: Guilford Press, 2004:259-299.
55. Dutta A, McKie S, Deakin JF. Ketamine and other potential glutamate antidepressants. Psychiatry Research 2015; Vol. 225, issue 1-2:1-13. [DOI:]
56. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
57. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving crossover trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
58. Feighner JP, Robins E, Guze SB, WoodruffRA, Winokur G, Munoz R. Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry 1972;26(1):57-63.
59. Furukawa TA, Guyatt GH, Griffith LE. An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology 2002;31(1):72-6.
60. Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analysis. International Clinical Psychopharmacology 2005;20(1):49-52.
61. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7-10.
62. Furukawa TA, Watanabe N, Omori IM, Montori VM, Guyatt GH. Association between unreported outcomes and effect size estimates in Cochrane meta-analyses. JAMA 2007;297(5):468-70.
63. Furukawa TA, Akechi T, Azuma H, Okuyama T, Higuchi T. Evidence-based guidelines for interpretation of the Hamilton Rating Scale for Depression. Journal of Clinical Psychopharmacology 2007;27(5):531-4.
64. Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet 2013;381(9878):1672-82.
65. McMaster University (developed by Evidence Prime, Inc.). GRADEproGDT: GRADEpro Guideline Development Tool [www.guidelinedevelopment.org]. 2015. Hamilton: McMaster University (developed by Evidence Prime, Inc.), August 28th 2015.
66. Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI:]
67. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville (MD): U.S. Department of Health and Human Services, 1976.
68. Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS. Interpreting treatment effects in randomised trials. BMJ 1998;316(7132):690-3.
69. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62.
70. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
71. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
72. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
73. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
74. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
75. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. Journal of Neuroscience 2007;27(43):11496-500.
76. Honey RA, Turner DC, Honey GD, Sharar SR, Kumaran D, Pomarol-Clotet E. Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory. Neuropsychopharmacology 2003;28:2037-44.
77. Howland RH. Induction of mania with serotonin reuptake inhibitors. Journal of Clinical Psychopharmacology 1996;16(6):425-7.
78. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry 2002;59(6):530-7.
79. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II. disorder. Archives of General Psychiatry 2003;60(3):261-9.
80. Kavalali ET, Monteggia LM. Synaptic mechanisms underlying rapid antidepressant action of ketamine. American Journal of Psychiatry 2012;169(11):1150-6.
81. Kendall T, Morriss R, Mayo-Wilson E, Marcus E, Guideline Development Group. Assessment and management of bipolar disorder: summary of updated NICE guidance. BMJ 2014;349:g5673.
82. Kendell SF, Krystal JH, Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opinion on Therapeutic Targets 2005;9(1):153-68.
83. Kubitz N, Mehra M, Potluri RC, Garg N, Cossrow N. Quinn TJ. Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database. PLoS ONE 2013;8(10):e76882.
84. Magni LR, Purgato M, Gastaldon C, Papola D, Furukawa TA, Cipriani A, et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI:]
85. Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, et al. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 2012;26(3):189-204.
86. McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychological Medicine 2015; Vol. 45, issue 4:693-704.
87. Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Archives of General Psychiatry 2011;68(3):241-51.
88. Moher D, Liberati A, TetzlaffJ, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. BMJ 2009;339:2535.
89. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-9.
90. Morgan CJA, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 2010;105:121-33.
91. Muller MJ, Himmerich H, Kienzle B, Szegedi A. Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). Journal of Affective Disorders 2003;77(3):255-60.
92. Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384(9947):1005-70.
93. Naughton M, Clarke G, O'Leary OF, Cryan JF, Dinan TG. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. Journal of Affective Disorders 2014;156:24-35.
94. Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA Jr, Charney DS. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annual Review of Pharmacology and Toxicology 2014;54:119.
95. Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate CA Jr. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biological Psychiatry 2009;65(2):181-4.
96. Purgato M, Papola D, Gastaldon C, Trespidi C, Magni LR, Rizzo C, et al. Paroxetine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI:]
97. Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Canadian Journal of Anaesthesia 1989;36(2):186-97.
98. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
99. Salvadore G, Quiroz JA, Machado-Vieira R, Henter ID, Manji HK, Zarate CA. The neurobiology of the switch process in bipolar disorder: a review. The Journal of Clinical Psychiatry 2010;71(11):1488-501.
100. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Archives of General Psychiatry 1978;35(6):773-82.
101. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. Journal of Clinical Epidemiology 2000;53(11):1119-29.
102. Suh T, Gallo JJ. Symptom profiles of depression among general medical service users compared with specialty mental health service users. Psychological Medicine 1997;27(5):1051-63.
103. Taylor DM, Cornelius V, Smith L, Young AH. Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. Acta Psychiatrica Scandinavica 2014;130(6):452-69.
104. Thomas SP, Nandhra HS, Jarvaraman A. Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD). Journal of Mental Health 2010;19(2):168-75.
105. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, et al. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). European Neuropsychopharmacology 1997;7(1):9-24.
106. Wang J, Jing L, Toledo-Salas JC, Xu L. Rapid-onset antidepressant efficacy of glutamatergic system modulators: the neural plasticity hypothesis of depression. Neuroscience Bulletin 2015;31(1):75-86.
107. Ware JE Jr, Sherbourne CD. The MOS 36-item short form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992;30(6):473-83.
108. Ware JE, Kosinski M, Keller SD. SF-12: How to Score the SF-12. Physical and Mental Health Summary Scales. Lincoln (RI): QualityMetric Inc., 1998.
109. World Health Organization (WHO). The ICD-10 Classification of Mental and Behavioural Disorders. Geneva: WHO, 1992.
110. WHOQOL Group. The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties. Social Science and Medicine 1998;46(12):1569-85.
111. Wing JK, Beevor AS, Curtis RH, Park SBG, Burns A. Health of the nation outcome scales (HoNOS). Research and development. British Journal of Psychiatry 1998;172:11-8.
112. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 2006;63(8):856-64.
113. Zavodnick AD, Ali R. Lamotrigine in the treatment of unipolar depression with and without comorbidities: a literature review. Psychiatric Quarterly 2012;83:371-83.